Search research articles
Contact Us
Filters
Showing results (61-70 of 167) with videos related to
Page
of 17
Sort By:
American Journal of Clinical Pathology
|
December 14, 2020
Mastocytosis
Alexandar Tzankov, Eric Duncavage, Fiona E Craig, et al.
Leukemia & Lymphoma
|
October 10, 2009
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV
Sarah T Wilkinson, Diane R Fernandez, Shawn P Murphy, et al.
Blood Advances
|
June 28, 2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
W Richard Burack, Hongli Li, Diana Adlowitz, et al.
Haematologica
|
April 10, 2010
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma
Christopher J Stasik, Hiroaki Nitta, Wenjun Zhang, et al.
Blood
|
November 18, 2018
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
Xiaoyu Qu, Hongli Li, Rita M Braziel, et al.
American Journal of Clinical Pathology
|
December 28, 2020
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders
Katalin Kelemen, Leonie Saft, Fiona E Craig, et al.
Blood
|
February 7, 2019
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Eric D Hsi, Hongli Li, Andrew B Nixon, et al.
Leukemia & Lymphoma
|
January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520
Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.
British Journal of Haematology
|
October 23, 2015
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601
Brian G Till, Hongli Li, Steven H Bernstein, et al.
Cancer Research
|
May 29, 2015
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
Amit Dipak Amin, Soumya S Rajan, Winnie S Liang, et al.
Page
of 17
Search research articles
Search
Showing results (61-70 of 167) with videos related to
Sort By:
Page
of 17
American Journal of Clinical Pathology
|
December 14, 2020
Mastocytosis
Alexandar Tzankov, Eric Duncavage, Fiona E Craig, et al.
Leukemia & Lymphoma
|
October 10, 2009
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV
Sarah T Wilkinson, Diane R Fernandez, Shawn P Murphy, et al.
Blood Advances
|
June 28, 2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
W Richard Burack, Hongli Li, Diana Adlowitz, et al.
Haematologica
|
April 10, 2010
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma
Christopher J Stasik, Hiroaki Nitta, Wenjun Zhang, et al.
Blood
|
November 18, 2018
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
Xiaoyu Qu, Hongli Li, Rita M Braziel, et al.
American Journal of Clinical Pathology
|
December 28, 2020
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders
Katalin Kelemen, Leonie Saft, Fiona E Craig, et al.
Blood
|
February 7, 2019
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Eric D Hsi, Hongli Li, Andrew B Nixon, et al.
Leukemia & Lymphoma
|
January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520
Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.
British Journal of Haematology
|
October 23, 2015
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601
Brian G Till, Hongli Li, Steven H Bernstein, et al.
Cancer Research
|
May 29, 2015
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
Amit Dipak Amin, Soumya S Rajan, Winnie S Liang, et al.
Page
of 17